000753156 000__ 05588cam\a2200541Ma\4500
000753156 001__ 753156
000753156 005__ 20230306141542.0
000753156 006__ m\\\\\o\\d\\\\\\\\
000753156 007__ cr\un\nnnunnun
000753156 008__ 160101s2016\\\\sz\\\\\\o\\\\\001\0\eng\d
000753156 019__ $$a935252135
000753156 020__ $$a9783319249322$$q(electronic book)
000753156 020__ $$a3319249320$$q(electronic book)
000753156 020__ $$z9783319249315
000753156 020__ $$z3319249312
000753156 0247_ $$a10.1007/978-3-319-24932-2$$2doi
000753156 035__ $$aSP(OCoLC)ocn933587256
000753156 035__ $$aSP(OCoLC)933587256$$z(OCoLC)935252135
000753156 040__ $$aIDEBK$$beng$$epn$$cIDEBK$$dYDXCP$$dGW5XE$$dOCLCO$$dCOO$$dN$T$$dOCLCF$$dOCLCO$$dOCLCQ$$dOCLCO$$dEBLCP$$dOCLCO
000753156 049__ $$aISEA
000753156 050_4 $$aRC280.L8
000753156 08204 $$a616.99/42406$$223
000753156 08204 $$a610$$223
000753156 24500 $$aLung cancer and personalized medicine$$h[electronic resource] :$$bnovel therapies and clinical management /$$cAamir Ahmad, Shirish M. Gadgeel, editors.
000753156 260__ $$aCham :$$bSpringer,$$c©2016.
000753156 300__ $$a1 online resource.
000753156 336__ $$atext$$btxt$$2rdacontent
000753156 337__ $$acomputer$$bc$$2rdamedia
000753156 338__ $$aonline resource$$bcr$$2rdacarrier
000753156 4901_ $$aAdvances in experimental medicine and biology,$$x0065-2598 ;$$vv. 890
000753156 500__ $$aIncludes index.
000753156 5050_ $$aContributors; Preface; Contents; Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development; 1 Oncogenes, Tumor Suppressors and Targeted Therapeutics; 2 Somatic Copy Number Alterations and Coding Mutation Frequencies According to Lung Cancer Subtype; 2.1 Lung Adenocarcinoma; 2.1.1 EGFR; 2.1.2 KRAS; 2.1.3 BRAF; 2.1.4 HER2; 2.1.5 MET; 2.2 Squamous Cell Lung Cancer; 2.2.1 Somatic Copy Number Alterations in Squamous Cell Lung Cancer; 2.2.2 Somatic Coding Mutations in Squamous Cell Lung Cancer; 2.3 Small Cell Lung Cancer; 3 Genomic Translocations and Expressed Fusion Genes; 3.1 ALK
000753156 5058_ $$a3.2 ROS13.3 RET; 4 Challenges and Conclusions; References; Emerging Biomarkers in Personalized Therapy of Lung Cancer; 1 Introduction; 2 ROS1; 3 RET; 4 MET; 5 HER 2; 6 BRAF; References; Epithelial Mesenchymal Transition in Aggressive Lung Cancers; 1 Epithelial Mesenchymal Transition in Cancer: Overview; 2 Epithelial Mesenchymal Transition in Physiological Processes and Cancer; 3 Epithelial Mesenchymal Transition in Primary Tumor and Metastatic Dissemination; 4 Epithelial Mesenchymal Transition in Lung Cancer; 4.1 Epithelial Mesenchymal Transition and Prognosis in Lung Cancer
000753156 5058_ $$a4.2 Epithelial Mesenchymal Transition and Lung Cancer Progression4.3 Epithelial Mesenchymal Transition and Drug Resistance in Lung Cancer; 5 Therapeutic Potential of Targeting Epithelial Mesenchymal Transition in Lung Cancer; 6 Future Perspectives; References; The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer; 1 Introduction; 2 Cancer Stem Cells of the Lungs; 2.1 Markers Defining Lung CSCs and Their Potential Biological Implications; 2.1.1 CD133; 2.1.2 ALDH; 2.1.3 ABCG2; 2.1.4 Nanog; 2.2 Therapeutic Targeting of Lung CSC Markers; 3 Drug-Resistance
000753156 5058_ $$a3.1 Role of EMT in Drug-Resistance3.2 Role of CSCs in Drug-Resistance; 4 The Role of miRNAs; 4.1 MicroRNAs Associated with Chemoresistance; 4.1.1 miR-212; 4.1.2 The let-7 Family; 4.1.3 miRNAs Associated with EGFR; 4.2 MicroRNAs Associated with CSCs; 4.2.1 miR-34a; 4.2.2 miR-21; 4.2.3 The miR-200 Family; 5 Natural Agents and Their Synthetic Derivative as Anti-cancer Compounds; 5.1 BR-DIM; 5.2 Curcumin; 5.3 CDF; 6 Conclusions: The Future of CSCs and CSC-Targeted Treatment; References; The Microenvironment of Lung Cancer and Therapeutic Implications; 1 The Tumor Microenvironment: An Overview
000753156 5058_ $$a2 TME in Lung Cancer Prognosis3 TME in Lung Cancer Progression and Metastasis; 3.1 Cancer-Associated Fibroblasts (CAFs); 3.2 Endothelial Cells; 3.3 Hypoxia in Lung Cancer; 3.4 Inflammation; 3.5 Immune Cells; 3.5.1 T-Cells; 3.5.2 γδ T Cells; 3.5.3 Myeloid-Derived Suppressor Cells; 4 TME of Premetastatic Niche in the Lung; 5 The Contribution of TME to Therapeutic Resistance; 5.1 Contribution of TME to Resistance to Radiation Therapy; 5.2 Contribution of TME to Resistance to Antiangiogenic Therapies and EGFR-TKIs; 6 The TME as a Therapeutic Target in Lung Cancer
000753156 506__ $$aAccess limited to authorized users.
000753156 520__ $$aThis, the second of two volumes on personalized medicine in lung cancer, touches upon the recent progress in targeted drug development based on genomics; emerging biomarkers and therapeutic targets such as EMT, cancer stem cells, and the tumor microenvironment; current personalized clinical management and radiation therapy for lung cancers; and the promise of epigenetics and next-generation sequencing for the advancements towards personalized therapy of lung cancer patients. With chapters on state-of-the-art therapies and technologies written by leading experts working to develop novel companion diagnosis tools for the personalized treatment of lung cancer patients, this volume brings readers up-to-date by presenting the current knowledge on the efforts to make personalized management of lung cancer patients a reality.
000753156 588__ $$aDescription based on print version record.
000753156 650_0 $$aLungs$$xCancer$$xTreatment.
000753156 7001_ $$aAhmad, Aamir.
000753156 7001_ $$aGadgeel, Shirish M.
000753156 77608 $$iPrint version:$$z9783319249315
000753156 830_0 $$aAdvances in experimental medicine and biology ;$$vv. 890.
000753156 852__ $$bebk
000753156 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-319-24932-2$$zOnline Access$$91397441.1
000753156 909CO $$ooai:library.usi.edu:753156$$pGLOBAL_SET
000753156 980__ $$aEBOOK
000753156 980__ $$aBIB
000753156 982__ $$aEbook
000753156 983__ $$aOnline
000753156 994__ $$a92$$bISE